【摘要】：目的：探討阿托伐他汀對慢性阻塞性肺疾病急性加重期(Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD)患者血清粒細胞-巨細胞集落刺激因子（granulocyte-macrophage colony-stimulating factor，GM-CSF）水平及肺功能的影響。 方法：選擇2012年04月到2013年01月住院的44例AECOPD患者，將其隨機分為對照組(20例)和治療組(24例)。對照組按照診療常規(guī)予以AECOPD常規(guī)治療,治療組在常規(guī)治療基礎上加用阿托伐他汀20mg，每日一次口服。兩組均于入院第1天和治療14天行肺功能測定,并收集血清GM-CSF,采用ELISA方法測定血清GM-CSF的含量，最后對所得數(shù)據進行統(tǒng)計學分析：采用SPSS19.0統(tǒng)計學軟件進行數(shù)據處理，數(shù)據用x±s表示，兩組治療比較采用獨立樣本t檢驗，，治療前后的2個變量間的關系比較采用配對t檢驗，血清GM-CSF與FEV1%pre水平采用直線相關分析，檢驗水準α=0.05。 結果：1）治療組及對照組治療14天后FEV1%pre較治療前均顯著升高(P0.01)；2）治療組及對照組治療14天后血清GM-CSF均較治療前顯著降低(P0.01)；3）AECOPD患者血清GM-CSF與FEV1%pre呈負相關(P0.01)；4）治療組與對照組相比較治療14天后FEV1%pre、血清GM-CSF水平無顯著差異，無統(tǒng)計學意義(P0.05)。 結論：AECOPD患者經過治療后血清GM-CSF的水平較前降低，肺功能較前好轉，肺功能的改善可能與血清GM-CSF的水平的恢復有關。阿托伐他汀短期內未能明顯降低AECOPD患者血清GM-CSF的水平，改善肺功能，有待于今后對穩(wěn)定期COPD患者進行臨床觀察研究。
[Abstract]:Aim: to investigate the effects of Atto vastatin on serum granulocyte-giant cell colony-stimulating factor (GM-CSF) levels and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD). Methods: 44 patients with AECOPD were randomly divided into control group (n = 20) and treatment group (n = 24). The control group was treated with AECOPD according to the routine treatment routine, and the treatment group was treated with 20 mg of Atto vastatin once a day on the basis of routine treatment. Lung function was measured on the first day of admission and 14 days after treatment. Serum GM-CSF was collected and serum GM-CSF content was measured by ELISA method. Finally, the data were analyzed statistically: the data were processed by SPSS19.0 software. The data were expressed as x 鹵s, the two groups were treated with independent sample t test, the relationship between two variables before and after treatment was matched t test, the serum GM-CSF and FEV1%pre levels were analyzed by linear correlation analysis, the test level was 偽 0.05. Results (1) after 14 days of treatment, FEV1%pre in the treatment group and control group was significantly higher than that before treatment (P0.01). The serum GM-CSF in the treatment group and control group was significantly lower than that in the control group after 14 days of treatment (P0.01). There was a negative correlation between serum GM-CSF and FEV1%pre in the AECOPD patients (P0.01). 4) there was no significant difference in serum GM-CSF level between the treatment group and the control group after 14 days of treatment (P0.05). Conclusion after treatment, the level of serum GM-CSF and pulmonary function were decreased and the improvement of pulmonary function might be related to the recovery of serum GM-CSF. Atto vastatin could not significantly reduce the level of serum GM-CSF and improve pulmonary function in patients with AECOPD in a short time. The clinical observation and study of stable COPD patients were needed in the future.
【學位授予單位】：青海大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：R563

【參考文獻】

相關期刊論文 前9條

1 王月州;;COPD患者治療前后血清NO、NOS和GM-CSF檢測的臨床意義[J];放射免疫學雜志;2011年06期

2 王媛媛;李國平;;粒細胞-巨噬細胞集落刺激因子在COPD中的研究進展[J];西南軍醫(yī);2012年01期

3 白春學;COPD的炎癥和抗炎研究進展[J];臨床肺科雜志;2005年05期

4 王永彬;王偉;;辛伐他汀對COPD患者細胞凋亡和炎癥因子的干預作用[J];山東大學學報(醫(yī)學版);2009年08期

5 陳旭東;王偉;王永彬;;辛伐他汀對COPD大鼠模型炎癥的干預作用[J];山東大學學報(醫(yī)學版);2010年04期

6 楊永華;陳炯;;粒細胞巨噬細胞集落刺激因子在創(chuàng)面愈合中的應用進展[J];實用醫(yī)學雜志;2008年19期

7 張平;李衛(wèi)東;;辛伐他汀對慢性阻塞性肺疾病大鼠腫瘤壞死因子-α表達的影響及機制[J];中國藥物與臨床;2010年04期

8 仝重芳;李衛(wèi)東;趙卉;岳翠萍;張敏艷;;辛伐他汀對慢性阻塞性肺疾病大鼠白細胞介素-6基質金屬蛋白酶-9表達的影響[J];中國藥物與臨床;2011年03期

9 夏書月;康健;何巍;許曉陽;何曉琳;王實;;辛伐他汀對COPD急性加重期患者誘導痰血管內皮生長因子水平和肺功能的影響[J];中國呼吸與危重監(jiān)護雜志;2010年03期

本文編號：2142064